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Abstract
Background: Atherosclerosis is regarded as a combination of two major separate diseases: atherosis and sclerosis.
Sclerotic component depends on deterioration of elastic properties of the aortic wall and is called aortic stiffness.
The most valuable, non-invasive method of aortic stiffness assessment is echocardiography, which allows to calculate
the aortic stiffness index (ASI). ASI is an independent predictor of all-cause and cardiovascular mortality in different
groups of patients. The main aim of study was the assessment of the aortic reverse remodeling in patients with
end-stage renal disease (ESRD) after renal transplantation (RT).
Methods: Study group involved 42 patients aged 43.3 ± 12.6 years, including 19 women aged 49.9 ± 10.9 years
and 23 men aged 41.5 ± 12.91 years, who have undergone RT from non-related renal transplant donors, The
study protocol has been consisted of 5 stages: 1 week after RT, 3 months after RT, 6 months after RT, 1 year after
RT and 3 years after RT. The echocardiographic examination was performed and measurements of Aomax, Aomin
were done. On the base of obtained parameters ASI, aortic distensibility (AD) and aortic strain (AS) were calculated
according to adequate formulas.
Results: The improvement of indices characterizing the elastic properties of aorta were noted. These changes attained
the statistically significant level only at the end of the observation. ASI just after RT was equal – 4.65 ± 1.58, three
months after RT – 4.54 ± 1.49, six months after RT – 4.59 ± 1.61, one year after RT – 4.35 ± 1.21 and three years
after RT – 3.35 ± 1.29, while AD reached respectively – 6.55 ± 3.76 cm2/dyn−110−6 just after RT, − 6.38 ± 3.42 cm2/dyn−110−6
three months after RT, − 6.53 ± 3.60 cm2/dyn−110−6 six months after RT, − 6.48 ± 2.79 cm2/dyn−110−6 one year
after RT and – 8.03 ± 3.95 cm2/dyn−110−6 three years after RT. Noted AS values were equal – 6.61 ± 4.05%, just
after RT, − 6.40 ± 3.58% three months after RT, − 6.56 ± 3.76%, six months after RT, − 6.45 ± 2.80% one year after
RT, − 8.01 ± 3.97%. and three years after RT. The exact analysis of parameters concerning aortic function showed
that to achieve ASI, AD and AS improvement, long time was needed, because the most significant changes of
these indices were observed only between 1 year and 3 years after RT.
Conclusions: There is a relationship between renal transplantation and improvement of the aortic elastic properties.
The recovery of the renal function allows to initiate the reparative processes leading to at least partial restitution of the
structure and features of the aorta, which is called reverse remodelling. Improvement of aortic wall elastic properties
after renal transplantation is a continuous and prolonged process.
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Background
According to Windkessel’s concept [1] arterial system is
the vascular network, which allows to modify an intermit-
tent stream of blood outflowing from the heart to a con-
tinuous and stable blood flow through smaller vessels and
capillaries. Among the many factors affecting the proper
functioning of the system, one of the most important seems
to be the compliance of the vessel wall, which is able to
adapt (flow-dependent changes in diameter, cross sectional
area of vessels) in response to changes in the pressure of
blood flow [2]. A general term describing the resistance to
deformation of the vessel under the influence of blood
pressure is stiffness [3, 4].
Number of factors plays the role in the pathogenesis
of aortic stiffness. Both physiological ones, which are
especially important from a clinical point of view, as
well as pathological, resulting from diseases directly or
indirectly affecting the cardiovascular system, should
be taken into consideration. It has been shown that the
elastic properties of the aorta deteriorate with age.
Except the age, also sex plays important role, because
the process of stiffening of the aorta in women occurs
about 10 years later than in men [5, 6]. The aging of
the body is a crucial factor leading to reduced elasticity
as a result of changes in the structure of collagen and
elastin. However, congenital abnormalities of these
proteins cannot be excluded, too. The study of Madeley et
al. [7] indicates the important role of fibrillin-1 genotype
in the pathogenesis of the aortic stiffness.
From the pathophysiological point of view, a common
cause of aortic stiffness is undoubtedly atherosclerosis.
Furthermore, atherosclerosis is now considered a com-
bination of two major separate diseases: atherosis and
sclerosis. Atherosis, developing as a result of the forma-
tion of atherosclerotic plaques, is a complicated process,
in which inflammation plays a key role and one of the
main and most common consequences of this condition
is calcification of the plaque. The second element forming
part of atherogenesis development is the deterioration of
the large arteries elastic properties, which is defined as
stiffness. Also crucial importance of metabolic factors
like diabetes or end-stage renal disease (ESRD) should
be mentioned [8].
In patients with ESRD aortic stiffness is increased [9].
Also renal function was described as a determinant of
arterial stiffness despite of presence or absence of concomi-
tant coronary artery disease [10]. In histological evaluation
of arteries obtained from uraemic patients, some signs of
fibroelastic intimal thickening, elastic lamellae calcification,
and ground substance deposition were shown [11]. Re-
gardless of the described morphological changes, there
was proved, that in patients with ESRD, vascular endothe-
lial function associated with the accumulation in the plasma
of natural nitric oxide synthase (NOS) inhibitors, such as
asymmetric dimethylarginine (ADMA) is seriously im-
paired [12]. These data suggest that ADMA seems to
be a potential mediator linking the uremic milieu with
the endothelial dysfunction underlying the increased
arterial stiffness in patients with ESRD. Indeed ADMA
as the endogenous NOS inhibitor accumulates in time
of renal function deterioration [13].
Aortic stiffness affects the function of conducting
through the aorta elevated blood pressure and changes
the pressure curve, thus increasing the left ventricle
(LV) afterload. This causes left ventricle hypertrophy
(LVH) and also adversely modifies its diastolic and
systolic function. Thickened LV becomes particularly
sensitive to ischemia and both of these abnormalities
increase the heterogeneity of the electrical activity of
the heart [14].
Aim of the study
The possibility of removal of the factor promoting the
phenomenon of the vessel wall stiffening seems to be
the most interesting non-pharmacological intervention.
Considering the complex pathogenesis of aortic stiffness
and limitations allowing only to modify the causative
factors, mentioned action is purely hypothetical. The
reasonable model of this situation represents a renal
transplantation (RT), which due to curing the patient
of one of the potential causes of aortic stiffness, gives
hope to discover, as yet unexplored, modified elastic
properties of the aorta.
The main objective of the study was, therefore, to
evaluate the phenomenon of reverse remodeling of the
aorta in patients with ESRD after RT.
Methods
This is a small-scale progressive study using current
echocardiographic methodology. Forty two patients,
aged 43.3 ± 12.6 years, including 19 women aged 49.9 ±
10.9 years and 23 men aged 41.5 ± 12.91 years were
enrolled to the study group. All patients have undergone
RT from unrelated donors because of ESRD. In every
patient examined in the study, the arteriovenous fistula
was closed. Reasons for ESRD in the study group in-
cluded: glomerulonephritis, diabetes mellitus, polycystic
kidney degeneration, hypertensive nephrosclerosis, chronic
tubulointerstitial nephritis and other unspecified causes
(Fig. 1). Exclusion criteria were: heart failure, manifest
coronary artery disease, patent arterio-venous fistula and
unstable graft function at any time during the follow-up.
To ensure that only ESRD related causes of aortic dys-
function were assessed, patients with mild to severe aortic
valve disease on echocardiography were excluded from
the study. All patients were treated with the immunosup-
presion regimen, which included methylprednisolone,
mycophenolate mofetil and cyclosporine microemulsion
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or tacrolimus (Table 1). Treatment prior to RT are shown
in Table 1.
In all patients a detailed medical history and physical
examination were carried out. The following clinical
parameters were evaluated: age, sex, duration of dialysis
treatment to RT.
The study protocol consisted of 5 stages:
Phase I - evaluation about 1 week after RT.
Phase II - evaluation about 3 months after RT.
Phase III - evaluation about 6 months after RT.
Phase IV - evaluation about 1 year after RT.
Phase V - evaluation about 3 years after RT.
During the subsequent phases the following measure-
ments were performed:
Phase I:
 anthropometric measurements: height, weight.
On the basis of these measurements the following
indicators: body surface area (BSA), body mass index
(BMI) have been calculated, using the appropriate
formulas,
 measurements of pressure: systolic blood pressure
(SBP), diastolic blood pressure (DBP). On the basis
of these measurements mean blood pressure (MBP)
and puls pressure (PP) have been calculated, using
the appropriate formulas,
 heart rate (HR) measurement,
 transthoracic echocardiography (TTE) using the
probe 2.5–3.5 MHz cooperating with
echocardiography ultrasound system Sonos 5500
(Philips, Andover, MA, USA) and Sonos 7500
(Philips, Andover, MA, USA) was performed. In
order to objectify the obtained data, the
examination was conducted without prior
detailed knowledge of the evaluated patient’s
clinical data. All echocardiographic measurements
were carried out according to the recommendations
of the American and the European Society of
Echocardiography [15].
 M-mode echocardiography has been performed
under the control of two-dimensional imaging in
the parasternal longitudinal axis. Aortic diameters
were measured perpendicular to its long axis by
TTE. In order to evaluate the parameters relating
to the ascending aorta, ultrasonic beam was
located 3 cm above the site of the aortic valve
leaflets coaptation at the proximal tubular portion
of the ascending aorta. Echocardiographic
measurements were made using leading edge to
leading edge method [16, 17]. Valid values in
healthy subjects assessed by this method are as
follows: at the end-diastole–28.5 ± 3.8 mm; at the
mid-systole - 30.0 ± 3.6 mm [18]. The following
parameters were recorded:
 aortic maximal diameter - Aomax, [mm] –
corresponding to the systolic dimension of the
aorta; was measured at the time of full opening of
the aortic valve leaflets,
 aortic minimal diameter - Aomin, [mm] –
corresponding to the diastolic dimensions of the
aorta; was measured on the peak of QRS wave of
simultaneously recorded electrocardiogram.
 interventricular septum systolic diameter -
IVSSd, [mm],
Fig. 1 The etiology of ESRD in patients after RT
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 interventricular septum diastolic diameter -
IVSDd, [mm],
 posterior wall systolic diameter - PWSd, [mm],
 posterior wall diastolic diameter – PWDd, [mm],
 left ventricle endsystolic diameter LVESd, [mm],
 left ventricle enddiastolic diameter – LVEDd, [mm].
Then, on the basis of the above listed planimetric mea-
surements the functional indices of the aorta have been
calculated [3, 19]:
 aortic strain – AS, [%]; AS = (Aomax – Aomin)/Aomin,
 aortic distensibility – AD, [cm2/dyn−110−6]; AD = [2 x
(Aomax – Aomin)]/[(Aomin x PP)]; PP was the
difference in SBP and DBP measured at the right
brachial artery simultaneously with measuring the
dimensions of the aorta [17, 20],
 aortic stiffness index – ASI, [n]; ASI = log {[SBP/
DBP/(Aomax – Aomin)]/Aomin}; SBP and DBP were
measured on the right brachial artery simultaneously
with assessing the dimensions of the aorta.
Based on planimetric parameters, indices of LV struc-
ture and function have been calculated as follows [21, 22]:
 left ventricle endsystolic volume – LVESV, [ml] -
calculated according to the Teichholz formula:
LVESV = [7/(2,4 + LVESd)] x [LVESd]3,
 left ventricle enddiastolic volume - LVEDV, [ml] -
calculated according to the Teichholz formula:
LVEDV = [7/(2,4 + LVEDd)] x [LVEDd]3,
 left ventricle stroke volume – SV, [ml] - calculated
according to the formula: SV = LVEDV – LVESV,
 stroke index – SI, [ml/m2] - calculated according to
the formula: SI = SV/BSA,
 cardiac output – CO, [l/min] - calculated according
to the formula: CO = SV x HR,
 cardiac index – CI, [l/min/m2] - calculated according
to the formula: CI = CO/BSA,
 left ventricle ejection fraction – EF, [%] - calculated
according to the formula: EF = [(LVEDV – LVESV)/
LVEDV] x 100,
 left ventricle shortening fraction – FS, [%] -
calculated according to the formula: FS = [(LVEDd –
LVESd)/LVEDd] x 100,
 left ventricle mass – LVM, [g] - calculated according to
the formula [23]: LVM= 1,04 x [(IVSDd + PWDd+
LVEDd)3] - 13,6 g
 left ventricle mass index – LVMI, [g/m2] - calculated
according to the formula: LVMI = LVM/BSA.
 left ventricle hypertrophy - LVH was recognized if [24]:
 LVMI > 131 g/m2 in men,
 LVMI > 100 g/m2 in women.
Statistical analysis
The data were statistically analyzed using the Statistica
6.0 software (StatSoft Inc.). Quantitative and qualitative
data of the study subgroups and clinical variables were
analyzed descriptively. The number of patients in particular
groups in statistical analyzes in the tables was marked with
the symbol “n”. Differences between quantitative variables
Table 1 Baseline characteristics of the study population
Characteristic Value
age [years] 43.3 (±12.6)
gender (men/women) [n (%)] 23 (54.8%)/19 (43.2%)
time on dialysis until RT [months] 36.18 (±22.72)
haemoglobin [g/dl] 12.25 (±3.67)
natrium [mmol/l] 139.0 (±2.71)
potassium [mmol/l] 4.7 (±1.31)
magnesium [mmol/l] 0.99 (±0.28)
calcium [mmol/l] 2.54 (±0.24)
phosphorus [mmol/l] 1.68 (±0.49)
Ca X P [mg2/dl2] 52.47 (±13.94)
parathormone [pg/ml] 734.3 (±656.8)
creatinine [μmol/l] 539.24 (±245.75)
eGRF [ml/min/1,73 m2] 10.9 (±7.68)
urea [mmol/l] 9.74 (±5.72)
total protein [g/l] 75.0 (±14.3)
albumin [g/l] 4.6 (±1.13)
hs-CRP [mg/l] 2.12 (±2.22)
total cholesterol [mg/dl] 219.0 (±67.2)
LDL-cholesterol [mg/dl] 131.0 (±44.15)
HDL-cholesterol [mg/dl] 66.1 (±24.55)
triglycerides [mg/dl] 214.3 (±67.64)
glucose [mg/dl] 90.77 (±47.19)
troponin T [μg/l] 0.018 (±0.037)
myoglobin [ng/ml] 183.5 (±171.1)
creatine kinase [U/l] 81.1 (±86.2)
creatine kinase myocardial bound [U/l] 17.4 (±8.12)
treatment prior to RT
ACE-inhibitors/sartans [n (%)] 0 (%)
calcium blockers [n (%)] 40 (95.2%)
beta-blockers [n (%)] 23 (54.8%)
alfa-blockers [n (%)] 5 (11.9%)
clonidine [n (%)] 31 (73.8%)
statins [n (%)] 3 (7.1%)
immunosuppression
methylprednisolone [n (%)] 42 (100%)
mycophenolate mofetil [n (%)] 42 (100%)
cyclosporine [n (%)] 21 (50%)
tacrolimus [n (%)] 21 (50%)
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relating to the normal distribution were analyzed using
Student’s t test for dependent variables. In order to com-
pare several variables the analysis of variance (ANOVA) for
the dependent and independent variables was used. In the
case of dependent variables (further measurements in
patients after RT) analysis of Friedman variance ranks
(Friedman ANOVA) was used and Kendall’s coefficient
of concordance was provided. The comparative analysis
of multiple dependent variables was additionally calculated
by ANOVA test with repeated measurements. In order to
determine the relationship between two variables the
Spearman rank correlation coefficient was used.
P value 0.05 was assumed as the level of significance
of statistical tests. In the case of p-value less than 0.00001,
0.0001, or 0.001 its value was presented as a significance
level of p <0.00001, p <0.0001 and p <0.001, respectively.
In other situations, the exact result was given.
Results
Characteristics of the study group
The study group consisted of 42 patients including 19
women and 23 men after RT due to ESRD. Table 1 shows
the baseline characteristics of the study population.
A detailed analysis of changes in HR, pressures and
anthropometric data are presented in Table 2. HR during
the observation gradually decreases and after a period of
3 years was significantly lower than at the baseline (Table 2).
Systolic blood pressure in the course of the follow-up
steadily significantly declined, while diastolic blood pres-
sure remained unchanged (Table 2). As a result, the PP
reduction was statistically significant (Table 2).
Progressive reduction of evaluated planimetric dimen-
sions of the LV was noted. At the end of the follow-up, all
planimetric indices were significantly lower than immedi-
ately after surgery. The dynamics of these changes, how-
ever, was different depending on assesed parameters in
subsequent periods of observation (Table 3). This was
accompanied by the change of evaluated LVH indices. After
the 3-years follow-up planimetric indices were considerably
lower in comparison with the baseline, but the statistical
significance of these reductions was proved only after one
year follow-up (Table 3). As a result of the planimetric
parameters significant decline, the volumetric parameters
of LV decrease was observed. Their values at the end of the
observation became significantly lower than at the
beginning, but the dynamics of the particular parameters
behaved very individually (Table 3). Regarding the indices
of LV contractility significant changes in EF and FS were
observed (Table 3).
Comparative analysis of the ascending aorta dimensions
revealed a significant increase in the Aomax after 3 years
follow-up. This change, however, was statistically signifi-
cant only in the final phase of the follow-up. However
Aomin during the study remains unchanged (Table 4). As a
result of the changes of Aomax and accompanied,
described above, changes in the value of pressure, a
noticeable improvement of indicators characterizing
the stiffness of the aorta was observed. These changes,
however, reached statistical significance only at the
end of the follow-up (Table 4).
Analysis of changes in echocardiographic parameters
concerning the aorta during the 3-years follow-up
A detailed analysis of Aomax changes indicates that
differences concerning this parameter are extremely
subtle. Despite the significant changes found in the
Student’s t test indicating a statistically significant increase
of this dimension, dependent mainly on changes in the
final phase of the follow-up, simultaneous analysis of all
measurements in the test ANOVA with repeated mea-
surements did not reveal the significance of changes
(Fig. 2). In contrast, the same analysis performed using
Friedman Anova method confirmed the statistical sig-
nificance (Fig. 3).
Analogously, Aomin, evaluated by ANOVA with repeated
measures did not change significantly over the 3-years
follow-up (Fig. 4), but assessed using Friedman Anova
slightly but significantly decreased (Fig. 5).
These small changes of the aorta dimensions and the
previously discussed changes of pressure, caused that
differences in the functional indices of the aorta were
highly significant, regardless of the method of statistical












1 (n = 42) 2 (n = 42) 3 (n = 42) 4 (n = 42) 5 (n = 42) 1vs2 1vs3 1vs4 1vs5 2v3 3vs5 4vs5
HR [n/min] 76.97 (±8.86) 75.4 (±7.82) 75.8 (±8.32) 73.2 (±7.97) 72.9 (±37.46) 0.453 0.247 0.123 0.034 0.875 0.082 0.142
SBP [mmHg] 138.8 (±13.0) 135.8 (±12.8) 135.3 (±11.4) 134.6 (±14.5) 133.6 (±10.5) 0.023 0.027 0.009 <0.001 0.659 0.219 0.342
DBP [mmHg] 87.7 (±8.2) 86.3 (±10.2) 86.8 (±8.7) 87.6 (±8.4) 88.3 (±7.4) 0.723 0.572 0.745 0.561 0.435 0.563 0.843
PP [mmHg] 51.0 (±9.1) 50.2 (±8.2) 49.3 (±9.1) 46.8 (±8.2) 45.3 (±6.0) 0.356 0.281 0.002 <0.001 0.265 0.017 0.453
BSA [m2] 1.87 (±0.12) 1.87 (±0.12) 1.87 (±0.12) 1.86 (±0.13) 1.86 (±0.13) NA NA NA NA NA NA NA
BMI [kg/m2] 24.05 (±3.78) 24.05 (±3.78) 24.05 (±3.78) 24.11 (±3.54) 24.21 (±3.67) NA NA NA NA NA NA NA
NA not applicable
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analysis. Moreover, detailed analysis showed that changes
of ASI, AD and AS require a long time to reveal, because
the most significant differences between the observations
were noticed between a year and three years after RT
(Figs. 6, 7, 8, 9).
Analysis of the relationship between ASI and the selected
echocardiographic parameters
Using the Spearman’s rank correlation a detailed analysis
of ASI with the tested echocardiographic parameters
was carried out. Among the many echocardiographic
indices obtained just after RT significant correlation with
ASI and LVESd, PWSd, IVSSd, LVESV, LVM and EF was
observed (Table 5). The analysis of parameters obtained
at the end of a 3-year follow-up showed a statistically
significant relationship between LVESd, PWSd, LVEDV,
LVESV, EF, FS and the ASI (Table 5).
Multivariate analysis performed by multiple regression
revealed that among the echocardiographic parameters
analyzed immediately after RT, PWSd LVH and AD were
independently associated with ASI (Table 6), but the
assessment made after the 3-years follow-up showed that
LVESd, PWSd, LVESV, FS and AS were independently
associated with ASI (Table 7).
Discussion
The conducted comparative assessment of the planimetric
parameters of the LV showed a reduction of its dimensions
during the 3-years follow-up, with a significant reduction
of LVEDd, LVESd, LVEDV and LVESV noticeable already












1 (n = 42) 2 (n = 42) 3 (n = 42) 4 (n = 42) 5 (n = 42) 1vs2 1vs3 1vs4 1vs5 2v3 3vs5 4vs5
LV dimensions
LVEDd [mm] 52.5 (±5.1) 50.7 (±4.5) 50.5 (±4.6) 50.1 (±4.7) 49.7 (±4.8) 0.047 0.017 0.001 <0.001 0.953 0.072 0.247
LVESd [mm] 35.1 (±5.5) 34.6 (±3.7) 34.4 (±4.3) 33.9 (±4.9) 32.0 (±4.7) 0.153 0.141 0.011 0.004 0.580 0.007 0.009
PWDd [mm] 12.4 (±1.4) 12.2 (±1.6) 11.9 (±1.3) 11.8 (±1.7) 11.2 (±1.2) 0.91 0.01 0.233 <0.001 0.684 0.001 0.072
PWSd [mm] 15.3 (±1.2) 16.3 (±1.5) 16.6 (±2.2) 16.0 (±2.3) 17.4 (±2.0) 0.125 0.007 0.580 <0.001 0.450 0.001 0.027
IVSDd [mm] 13.4 (±1.4) 13.3 (±0.9) 13.0 (±0.9) 12.1 (±0.8) 11.8 (±1.3) 0.366 0.363 0.003 <0.001 0.142 0.01 0.03
IVSSd [mm] 16.1 (±1.5) 16.3 (±1.3) 17.6 (±2.0) 16.8 (±2.0) 17.3 (±1.9) 0.680 <0.001 0.034 <0.001 0.175 0.523 0.980
LVM indices
LVM [g] 329.5 (±73.4) 330.1 (±77.2) 323.0 (±74.9) 309.9 (±74.9) 283.9 (±62.0) 0.857 0.254 0.008 <0.001 0.189 <0.001 0.007
LVMI [g/m2] 173.9 (±38.6) 173.4 (±34.9) 171.2 (±35.6) 165.3 (±34.2) 149.3 (±33.0) 0.784 0.243 0.011 <0.001 0.124 <0.001 0.004
LV volumetric parameters
LVEDV [ml] 134.5 (±29.2) 124.2 (±31.3) 123.3 (±28.9) 122.2 (±34.5) 118.5 (±25.7) 0.012 0.009 0.002 0.001 0.834 0.052 0.274
LVESV [m] 53.25 (±19.90) 50.13 (±13.56) 50.43 (±15.61) 48.56 (±18.52) 42.35 (±15.34) 0.146 0.118 0.021 0.005 0.439 0.008 0.011
SV [ml] 81.31 (±19.36) 78.9 (±15.60) 77.8 (±17.62) 76.5 (±21.1) 76.23 (±18.05) 0.033 0.028 0.023 0.013 0.486 0.754 0.765
Cardiac output parameters
CO [l/min] 6.16 (±0.76) 5.81 (±0.59) 5.77 (±0.71) 5.54 (±0.82) 5.55 (±0.68) 0.019 0.014 0.011 0.007 0.685 0.232 0.983
CI [l/min/m2] 3.29 (±0.49) 3.10 (±0.47) 3.09 (±0.51) 2.97 (±0.45) 2.98 (±0.51) 0.021 0.017 0.013 0.009 0.832 0.274 0.934
Contractility parameters
EF [%] 60.98 (±9.93) 59.25 (±8.92) 60.54 (±9.34) 61.03 (±10.11) 64.59 (±9.11) 0.865 0.659 0.184 0.008 0.236 0.009 0.018
FS [%] 33.36 (±7.01) 32.67 (±6.72) 33.02 (±7.34) 33.78 (±9.32) 35.83 (±6.58) 0.753 0.769 0.238 0.011 0.327 0.012 0.045
Table 4 Planimetric dimensions and functional indicators of the aorta in patients after RT
Parameter immediately after RT n = 42 3 years after RT n = 42 P
Aomax [mm] 33.17 (±4.06) 33.81 (±3.89) 0.049
Aomin [mm] 31.24 (±4.58) 31.41 (±4.34) 0.594
ASI [n] 4.65 (±1.58) 3.35 (±1.29) <0.001
AD [cm2/dyn−110−6] 6.55 (±3.76) 8.03 (±3.95) <0.001
AS [%] 6.61 (±4.05) 8.01 (±3.97) <0.001
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in the short term, after the first three months of observa-
tion. Similarly, the indices characterizing LVM also have
been considerably reduced, but the time necessary for the
existence of these changes was, as proven, much longer.
The greatest reduction in LVM and LVMI was observed
between measurement performed 1 year after RT and in
the final phase of follow-up.
In the current study, during the 3-years after RT, LVMI
decreased from 173.9 ± 38.6 g/m2 to 149.3 ± 33.0 g/m2.
These results are similar to those outlined by Parffrey et al.
[25], who found in patients after transplantation LVH
reduction of this parameter from 166 g/m2 to 135 g/m2.
Decreased LVM was accompanied by a reduction in its
dimensions, that was reflected by a significant reduc-
tion LVEDV of LVEDV from 116 ml/m2 to 89 ml/m2.
Montanaro et al. [26] in study conducted admittedly
in a small, because consisting of 23 individuals, group
of patients, demonstrated a reduction of LVMI from
Fig. 2 Changes Aomax during the 3-year follow-up of patients after RT. Trend change for the entire period of observation - test ANOVA with repeated
measurements and comparison of measurements in different periods of observation – Student’s t test for dependent variables
Fig. 3 Changes Aomax during the 3-year follow-up of patients after RT. Anova Friedman and Kendall’s coefficient of concordance
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161.4 g/m2 to 122.1 g/m2 after the 2-year follow-up.
The recruitment to achieve the observed positive
changes, however, is not only to perform the transplant,
but also to maintain the adequate function of the trans-
planted organ. Indeed, Ferreira et al. [27] have shown that
both, dimensions LV and LVM, decreased only in those
patients after RT, in which the function of the trans-
planted organ was correct, what was manifested, on the
one hand, as normalization of serum creatinine, and on
the other as the normalization of blood pressure. In
patients with poor-controlled mentioned above parame-
ters, favorable reverse LV remodeling do not occur. Re-
duction of LVM, together with a reduction in planimetric
and volumetric parameters of LV carries important prog-
nostic information. This was proven by Sharma et al. [28],
who underlined the fact, that LVESd and the maximum
thickness of the LV wall, subsequent to the calcification of
the mitral annulus, are independent predictors of survival
Fig. 4 Changes Aomin during the 3-year follow-up of patients after RT. Trend change for the entire period of observation - test ANOVA with repeated
measurements and comparison of measurements in different periods of observation – Student’s t test for dependent variables
Fig. 5 Changes of Aomin during the 3-year follow-up of patients after RT. Anova Friedman and Kendall’s coefficient of concordance
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after RT. They postulate to consider the recommendation
of these echocardiographic parameters as standard prog-
nostic factors used in assessing the risk of mortality in pa-
tients after RT.
Historically, LV systolic dysfunction was regarded as
the limitation for the selection of patients appropriate
for RT. That was probably the reason that observed in
the study group parameters of LV systolic function were
normal. However, initially normal EF and FS increased
after 3 years and the improvement of these parameters,
although seemingly little in absolute terms, was statisti-
cally significant. The data from the literature suggest
that the greatest benefit of RT in relation to the LV sys-
tolic function refers to patients with very impaired con-
tractility. Melchior et al. [29] investigated a group of 29
patients with low EF and showed an increase of the aver-
age EF from 37.8% to the value of almost normal, as
much as 52% over the short, because only 1-month
Fig. 6 Changes of ASI during the 3-years follow-up of patients after RT. Trend change for the entire period of observation - test ANOVA with repeated
measurements and comparison of measurements in different periods of observation – Student’s t test for dependent variables
Fig. 7 Changes of ASI during the 3-years follow-up of patients after RT. Anova Friedman and Kendall’s coefficient of concordance
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follow-up. Further observation showed further improve-
ments in contractility, because after a year of follow-up
EF was already 58.2%. Other studies conducted by Wali
et al. [30] confirmed the beneficial effect of RT on LV
systolic function. During the 6-month follow-up investi-
gators showed an increase in EF from 31.6% to 47.2%,
and over the next six months less dynamic growth of EF
to 52.2% were noted. Improvement of contractile func-
tion was accompanied by a significant improvement in
functional capacity expressed by a reduction in NYHA
class. Other studies, as well as the presented research,
indicate the growth of FS. Parfrey et al. [25] reported
that RT is associated with an increase in FS from 21.5%
to 33.4%. In all of these and most of other available stud-
ies the time of follow – up was relatively short and do
not exceed a year of observation. In this context, it
should be emphasized the importance of the current 3-
years follow-up, revealing that in the long term, patients
even with normal systolic function after RT could
achieve further benefits of this form of treatment.
Fig. 8 Changes of AD during the 3-year follow-up of patients after RT. Trend change for the entire period of observation - test ANOVA with repeated
measurements and comparison of measurements in different periods of observation – Student’s t test for dependent variables
Fig. 9 Changes of AS during the 3-year follow-up of patients after RT. Trend change for the entire period of observation - test ANOVA with repeated
measurements and comparison of measurements in different periods of observation – Student’s t test for dependent variables
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Indices of aortic function as ASI, AD and AS during
the 3-year follow-up improved significantly. It may indi-
cate, that changes occurring after RT allow for at least
partial retrieve of the aorta elastic properties. Evaluation
of the exact changes in the subsequent stages of the
observation proves that the beneficial effect of the final
transformation occurs between one year observation and
the assessment made at the end of the follow-up after
3 years. This proves that the process of returning elastic
properties of the aorta is a long-term phenomenon. Histo-
pathological examination of the arteries performed in
patients with ESRD indicates the presence of the process
of remodeling, which consists of two main elements:
atherosis and sclerosis [31, 32]. The coronary artery dis-
ease (CAD), as a form of arteriosclerosis, is particularly
associated with increased aortic stiffness. Arteriosclerosis
and atherosclerosis share similar pathobiologic processes
[3]. Coronary artery calcification is associated with impaired
aortic distensibility [33]. Arterial stiffness has long been
viewed as a consequence of long-standing hypertension,
which is the fixed component of kidney failure. However,
recent studies have suggested that arterial stiffness may
contribute to the pathogenesis of hypertension [34]. Other
comorbidities have a large effect on aortic stiffness.
Diabetes mellitus is independently associated with lower
aortic distensibility, increased arterial stiffness and impaired
flow-mediated dilatation [35]. Less common diseases like,
aortic regurgitation, congenital heart disease (bicuspid
aortic valve, tetralogy of Fallot), connective tissue disorders
(Marfan syndrome, Ehlers-Danlos syndrome), aortic coarc-
tation repair, hypertophic cardiomyopathy, can also cause
impairment of aortic elastic properties [3].
From an epidemiological point of view, RT improves
cardiovascular prognosis in this group of patients [36].
This improvement appears to be dependent on many
factors, among which the recovery of normal glomerular
filtration rate (GFR), enabling elimination of uremic toxins
[37] as well as better control of cardiovascular risk factors
[38] should be mentioned. The elastic properties of the
aorta may be affected by a medication taken by patients.
Mitchell et al. demonstrated, that long-term trandolapril
treatment is associated with reduced aortic stiffness [39].
The angiotensin receptor blockers (sartans) may produce
the same effect as ACE inhibitors. Treatment with ibersar-
tan improved arterial compliance, whereas inflammatory
and endothelial markers remained unchanged [40].
Additionally, it was proved, that in patients with chronic
kidney disease a combination of ACE inhibitor and sartans
allows to achieve even greater reduction of arterial stiff-
ness than the treatment with only one of mentioned drugs
[41]. Beta-blockers have different, often opposing action
on the arterial elastic properties. Nebivolol, which is a
selective beta-1 blocker with nitric oxide potentiating
vasodilatatory effect, has been shown to slightly decrease
the central pressure indices, when compared to atenolol
[42]. The calcium channel blocker were evaluated among a
large number of studies, where it proved to reduce central
blood pressure and arterial stiffness [43]. In patients with
CAD and normal blood pressure the treatment with statin
provided significant decrease of PWV and improvement of
arterial stiffness, what was not observed in patients with
CAD and hypertension [44]. But we should not forget that
the RT and the associated necessary drug therapy is
connected with the new, previously absent factors, poten-
tially adversely affecting the elastic properties of the aorta.
Among them essential therapy with cyclosporine, cortico-
steroids, azathioprine and mycophenolate mofetil should
be taken into consideration. These drugs, necessary to
maintain the graft, cause hypertension, stimulate LVH and
promote metabolic disorders as diabetes or hypercholes-
terolemia, potentially increasing the stiffness of the aorta.
Table 5 Correlation analysis ASI with echocardiographic
parameters in patients immediately after RT and after the
3-year follow-up
Parameter ASI
immediately after RT after 3 years follow-up
R P R P
LVEDd 0.145 0.358 0.037 0.813
LVESd 0.321 0.038 0.365 0.019
PWDd 0.143 0.365 0.037 0.813
PWST 0.321 0.038 0.346 0.026
IVSDd 0.126 0.425 0.103 0.513
IVSSd 0.313 0.043 0.085 0.590
LVEDV 0.003 0.980 0.349 0.014
LVESV 0.382 0.012 0.330 0.032
LVSV −0.028 0.857 −0.089 0.572
LVM 0.308 0.046 0.096 0.545
LVMI 0.017 0.913 0.286 0.066
EF −0.348 0.020 −0.367 0.027
FS −0.280 0.072 −0.321 0.024
Aomax −0.234 0.135 −0.223 0.213
Aomin 0.265 0.098 0.283 0.086
AD −0.603 <0.0001 −0.588 <0.0001
AS −0.619 <0.0001 −0.595 <0.0001
Correlation Spearman’s rank test
Table 6 Independent echocardiographic parameters related to








ASI PWSd 0.322 4.305 2.058 0.050
LVM −0.270 −0.006 0.003 0.050
AD −1.144 −0.462 0.171 0.014
Multiple linear regression analysis; model: R = 0,932, R2 = 0,870, p = 0,00002
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Consequently, the altered elastic properties of the aorta
represent the net, responsible for the disappearance of the
old risk factors of aortic stiffness and the appearance and
the potency of new ones. The evolution of aortic stiffness
after RT is poorly understood. While much is already
known about the relationship of ESRD and the pathogenesis
of aortic stiffness and its prognostic significance, the issue of
potential reverse remodeling of the aorta becomes a recent
interest of researchers. Studies provided up to date,
were based on the measurement of aorto-femoral pulse
rate, which is an admitted method of assessing of arterial
stiffness [45]. According to our knowledge, any study re-
garding aortic stiffness in patients after RT with using the
direct serial assessment of aortic functions, as it was done
in the present work, has not been carried out, yet. This
method has been successfully validated in other clinical
applications [3, 46].
Some authors have shown significant improvement in
arterial elasticity [47], while in other studies, no improve-
ment of the flexibility of vessels after RT has been observed
[48]. Bachelet-Rousseau et al. [49] did not show a signifi-
cant reduction in arterial stiffness after RT. Similarly, in the
study provided by Zoungas et al. [48], evaluating 36 patients
after RT, there were no improvement of elastic properties
of the aorta, however, mentioned authors demonstrated a
significant reduction of the femoral artery stiffness. All of
these studies were provided in the relatively short, because
the period of observation did not exceeding one year.
In these conditions currently obtained data are even
more valuable. Extending the time of patients monitoring,
allows to notice, that a phenomenon of favorable remodel-
ing of the aorta is possible, and to indicate that for the
assessment of the available test methods quite a long time
is required. In accordance with the results of the current
study are the data presented by de Lima et al. [50]. In the
group of 32 patients after RT followed for a relatively long
time, lasting 40 months, cited above authors showed an
improvement of indirect indices related to the stiffness of
the aorta such as LVH and carotid arterial compliance and
remodeling of the thickened at the baseline intima-media
complex of the carotid artery. Although the present study
indicate changes in the elastic properties of the arteries,
beneficial in the long-term period, it cannot be expected to
complete their restitution to the level observed in healthy
subjects [51]. This depends in part on the irreversible
changes, and partly on the appearance of previously
mentioned, new immunosuppressive treatment-related
factors, adversely modifying elastic properties of the aorta.
The efficiency of the transplanted organ and the presence
of subclinical inflammation features is also not without
significance [51].
Aortic stiffness is also in direct connection with the re-
jection of the graft. In the study provided by Bahous et al.
[52] it was demonstrated that the transplanted organ
injury long time after the RT increases the stiffness of the
aorta. This relationship occurs is a time-dependent
menner and it does not depend on such factors as age,
mean arterial pressure, atherosclerosis coexistence, drug
therapy and even the presence of the recipient’s own
kidneys. It is also not clear, whether these beneficial
changes of the aorta elastic properties are at least par-
tially dependent on decreasing, as far as the observation
period extends, blood pressure. In the present study, a
decrease in systolic blood pressure was observed over
almost all of the observation periods. In contrast, the
value of the pulse pressure evaluated at the beginning
of the study, was significantly reduced after a year of the
observation. Taking into consideration that the method of
the calculation of the aorta elastic properties indicators
includes both, the size of the aorta as well as blood pres-
sure and pulse pressure, it can not to be excluded that the
observed changes are not solely dependent on the regres-
sion changes or reverse remodeling of the aortic wall. On
the other hand, it is well known, that the stiffness of the
aorta and blood pressure are in mutual feedback [53]. This
relationship concerns, on the one hand, the pathogenic
mechanisms, resulting from elevated blood pressure,
which stimulate the stiffening of the aorta. On the other
hand, stiff aorta is the main cause of generating the higher
blood pressure, particularly in mean arterial pressure and
pulse pressure. This concept is supported by research
provided by Bachelet-Rousseau et al. [49]. The authors
although, as mentioned above, did not show during the
annual observation a significant improvement in the elastic
properties of the arteries, found a significant decrease of
both diastolic and mean pressure. This allowed the authors
to put forward suggestion, that perhaps the longer observa-
tion of patients would bring an answer, how the improving
Table 7 Independent echocardiographic parameters related to ASI in patients 3 years after RT
Dependent variable Independent variable β B st. dev. p
ASI LVESd −1.004 −2.893 0.0003 0.00007
PWSd −0.165 −1.342 0.00009 0.00004
LVESV 0.345 0.031 0.000009 0.0001
FS 0.389 0.084 0.000020 0.0001
AS −0.503 −0.167 0.000003 0.00001
Multiple linear regression analysis; model: R = 1,0, R2 = 1,0, p < 0,00001
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indices directly reflect the severity of the phenomenon of
arterial stiffness.
Based on currently obtained results and approachable
published data, it can be stated that the RT is a highly
effective method of treatment, which allows to reverse
the adverse structural and functional changes associated
with ESRD and renal replacement therapy.
Limitations of the study
We accept that this study has some limitations. This is a
small-scale study using current echocardiographic meth-
odology. The study group is not very large. This is due to
the fact that the kidney transplants are relatively rare in
Poland. In addition, the study included only patients who
remained in full observation, and in whom all echocardio-
graphic measurements was done. Another limitation is
that, causes of kidney failure may affect remodeling of the
aorta. Patients recruited to this study were being assessed
for kidney transplantation and may not be representative
of all patients with ESRD. We believe these results would
be relevant to other patients with more significant comor-
bid conditions. Use of ACE inhibitors, statin use, antihy-
pertensives and immunosuppression may have impact on
vascular parameters. Other factors including duration of
dialysis prior to renal transplant and biochemical markers
can also modify the elastic properties of the aorta. The
impact of the causes of ESRD and laboratory parameters
on echocardiographic indices were not analyzed for two
reasons. Firstly, the group was too small to analyze the
impact of the etiology on echocardiographic parameters
(eg. there was only 1 patient with chronic tubulo-interstitial
nephritis, and in 4 cases the etiology was not known). Stat-
istical analysis with such a small number of patients in the
subgroups does not make sense. Second, study was strictly
echocardiographic, what is highlighted in the title.
Conclusions
There is a relationship between renal transplantation
and improvement of the aortic elastic properties. With-
drawal of renal insufficiency allows to initiate the reparative
processes leading to at least partial restitution of structure
and function of the aorta, which is called reverse remodel-
ling. Improvement of aortic elastic properties after renal
transplantation is a continuous and prolonged process.
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